CSL Behring's mission is to discover, develop, and deliver our innovative therapies that improve the patients' quality of life.
Phase III Phase II/III Phase III AAT (CSL964) AAT (CSL964) Clazakizumab (CSL300) treatment study in MODULAATE IMAGINE trial Interleukin 6 Blockade Modifying Antibody- collaboration with BMT prevention study Mediated Graft Injury and Estimated CTN (NHLBI/NCI) Glomerular Filtration Rate (eGFR) Decline 1 2 3
CSL continues to provide medicines to patients around the world.
Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth.
CSL Behring and SAB Therapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic
We will enter into collaboration starting point, a confidentiality agreements to address partnership aspects, agreement may be required including the respect and protection of intellectual before both parties can commence property.
Innovation is in our DNA and is the core of everything we do at CSL Behring.
CSL / Momenta Collaboration •
Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19